Cardiac ankyrin repeat protein, a negative regulator of cardiac gene expression, is augmented in human heart failure

2002 ◽  
Vol 293 (5) ◽  
pp. 1377-1382 ◽  
Author(s):  
Oliver Zolk ◽  
Marcus Frohme ◽  
Alexander Maurer ◽  
Franz-Werner Kluxen ◽  
Bernd Hentsch ◽  
...  
2018 ◽  
Vol 123 (Suppl_1) ◽  
Author(s):  
Christoph D Rau ◽  
Jessica Wang ◽  
James Ohearn ◽  
Rozeta Avetisyan ◽  
Aldons J Lusis ◽  
...  

10.1186/gm158 ◽  
2010 ◽  
Vol 2 (6) ◽  
pp. 37 ◽  
Author(s):  
Mun-Kit Choy ◽  
Mehregan Movassagh ◽  
Lee Siggens ◽  
Ana Vujic ◽  
Martin Goddard ◽  
...  

2003 ◽  
Vol 284 (1) ◽  
pp. H268-H276 ◽  
Author(s):  
Charles Steenbergen ◽  
Cynthia A. Afshari ◽  
John G. Petranka ◽  
Jennifer Collins ◽  
Karla Martin ◽  
...  

Dilated cardiomyopathy, a disease of unknown etiology and pathogenesis, is associated with heart failure and compensatory hypertrophy. Although cell and animal models suggest a role for altered gene expression in the transition to heart failure, there is a paucity of data derived from the study of human heart tissue. In this study, we used DNA microarray profiling to investigate changes in the expression of genes involved in apoptosis that occur in human idiopathic dilated cardiomyopathic hearts that had progressed to heart failure. We observed altered gene expression consistent with a proapoptotic shift in the TNF-α signaling pathway. Specifically, we found decreased expression of TNF-α- and NF-κB-induced antiapoptotic genes such as growth arrest and DNA damage-inducible ( GADD) 45β, Flice inhibitory protein ( FLIP), and TNF-induced protein 3 ( A20). Consistent with a role for apoptosis in heart failure, we also observed a significant decrease in phosphorylation of BAD at Ser-112. This study identifies several pathways that are altered in human heart failure and provides new targets for therapy.


Circulation ◽  
1997 ◽  
Vol 95 (5) ◽  
pp. 1201-1206 ◽  
Author(s):  
Guy A. Haywood ◽  
Lars Gullestad ◽  
Tomohiro Katsuya ◽  
Howard G. Hutchinson ◽  
Richard E. Pratt ◽  
...  

2002 ◽  
Vol 22 (12) ◽  
pp. 4124-4135 ◽  
Author(s):  
Andrew N. Carr ◽  
Albrecht G. Schmidt ◽  
Yoichi Suzuki ◽  
Federica del Monte ◽  
Yoji Sato ◽  
...  

ABSTRACT Increases in type 1 phosphatase (PP1) activity have been observed in end stage human heart failure, but the role of this enzyme in cardiac function is unknown. To elucidate the functional significance of increased PP1 activity, we generated models with (i) overexpression of the catalytic subunit of PP1 in murine hearts and (ii) ablation of the PP1-specific inhibitor. Overexpression of PP1 (threefold) was associated with depressed cardiac function, dilated cardiomyopathy, and premature mortality, consistent with heart failure. Ablation of the inhibitor was associated with moderate increases in PP1 activity (23%) and impaired β-adrenergic contractile responses. Extension of these findings to human heart failure indicated that the increased PP1 activity may be partially due to dephosphorylation or inactivation of its inhibitor. Indeed, expression of a constitutively active inhibitor was associated with rescue of β-adrenergic responsiveness in failing human myocytes. Thus, PP1 is an important regulator of cardiac function, and inhibition of its activity may represent a novel therapeutic target in heart failure.


Sign in / Sign up

Export Citation Format

Share Document